(571) 447-5500

Prepared by Albert Yehaskel, Independent Advisor for Pharmaceutical Submissions

January 18, 2018

  • By submitting this form you will be joining the nearly 20,000 who receive the monthly EASeNews regulatory newsletter. Please note EAS never shares your information and you may unsubscribe at any time.

DMFs are regulatory submissions to FDA for drug substances, drug products, and/or container closures allowing FDA to review information such as confidential details about facilities, processes, components, or articles used in the manufacturing, processing, packaging, and storing of one or more APIs and/or human drugs. DMFs are at the discretion of the DMF holder and provided in the absence of relevant information in the CMC section of an application. These submissions support a third party’s application without revealing the information to the third party and maintain the confidentiality of proprietary information (e.g., a synthetic or manufacturing procedure) for the holder, allowing review of information by reviewers at FDA to support applications. The information contained in a DMF may be used to support an Investigational New Drug Application (IND), a New Drug Application (NDA/BLA), an Abbreviated New Drug Application (ANDA), another DMF, an Export Application, and any amendments and supplements to any of these applications.

Posted in Drugs, White Paper and tagged .